Cardlytics Inc

For the period ended Dec 31, 2024. Filed Mar 12, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 12, 2025

CDLX$1.63-10.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year Ended December 31,
	2024	2023	2022
Operating activities
Net Loss	$(189,304)	$(134,702)	$(465,264)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Credit loss expense	6,106	1,704	2,399
Depreciation and amortization	25,689	26,460	37,544
Amortization of financing costs charged to interest expense	1,633	1,648	1,595
Amortization of right-of-use asset	2,187	3,055	6,196
Impairment of goodwill and intangible assets	131,595	70,518	453,288
Loss on divestiture	—	6,550	—
Gain on debt extinguishment	(13,017)	—	—
Stock-based compensation expense	40,367	40,980	44,686
Change in contingent consideration	210	1,246	(128,174)
Other non-cash expense (income), net	1,481	(4,170)	6,589
Income tax benefit	—	—	(1,446)
Change in operating assets and liabilities:
Accounts receivable and contracts assets, net	12,497	(7,725)	(4,546)
Prepaid expenses and other assets	1,360	2,492	535
Accounts payable	499	239	(893)
Other accrued expenses	(6,644)	(7,492)	(9,516)
Partner Share liability	(16,350)	405	1,721
Customer Incentive liability	(7,133)	(1,393)	1,382
Net cash used in operating activities	(8,824)	(185)	(53,904)
Investing activities
Acquisition of property and equipment	(1,562)	(667)	(1,171)
Acquisition of patents	—	—	(175)
Capitalized software development costs	(17,736)	(11,725)	(12,140)
Business acquisitions, net of cash acquired	—	—	(2,274)
Proceeds from divestitures, net of cash divested	552	2,330	—
Net cash used in investing activities	(18,746)	(10,062)	(15,760)
Financing activities
Proceeds from issuance of debt	172,500	30,000	—
Principal payments of debt	(199,303)	(31)	(35)
Proceeds from termination of capped calls related to convertible notes	115	—	—
Proceeds from issuance of common stock	48,645	55	379
Settlement of contingent consideration	(14,167)	(50,050)	—
Repurchase of common stock	—	—	(40,000)
Equity issuance costs	(309)	—	(157)
Debt issuance costs	(6,037)	—	(174)
Net cash provided by (used in) financing activities	1,444	(20,026)	(39,987)
Effect of exchange rates on cash, cash equivalents and restricted cash	(110)	118	(1,926)
Net decrease in cash, cash equivalents and restricted cash	(26,236)	(30,155)	(111,577)
Cash, cash equivalents, and restricted cash — Beginning of period	91,830	121,985	233,562
Cash, cash equivalents, and restricted cash — End of period	$65,594	$91,830	$121,985

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year Ended December 31,
	2024	2023	2022
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheet:
Cash and cash equivalents	$65,594	$91,830	$121,905
Restricted cash	—	—	80
Total cash, cash equivalents and restricted cash — End of period	$65,594	$91,830	$121,985
Supplemental schedule of non-cash investing and financing activities:
Cash paid for interest	$6,119	$4,240	$2,381
Amounts accrued for property and equipment	$95	$579	$67
Amounts accrued for capitalized software development costs	$174	$40	$155
Issuance of common stock, net of issuance costs - Settlement Agreement (as defined below)	$27,451	$—	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.